Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1.079 INR | -0,09 % | +5,16 % | +26,39 % |
25/04 | El beneficio neto de Glenmark Lifesciences cae en el cuarto trimestre fiscal | MT |
01/04 | Glenmark Pharmaceuticals Limited anuncia cambios en su Consejo de Administración | CI |
Resumen de negocios
Número de empleados: 15 556
Ventas por actividad
INR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 123 049 | 100,0 % | 129 901 | 100,0 % | +5,57 % |
Ventas por región
INR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
India
34,4
%
| 43 809 | 35,6 % | 44 675 | 34,4 % | +1,98 % |
North America
25,0
%
| 32 035 | 26,0 % | 32 484 | 25,0 % | +1,40 % |
Europe
17,7
%
| 20 047 | 16,3 % | 23 047 | 17,7 % | +14,97 % |
Rest of the World
17,3
%
| 21 031 | 17,1 % | 22 414 | 17,3 % | +6,58 % |
Latin America
5,6
%
| 6 127 | 5,0 % | 7 281 | 5,6 % | +18,83 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 12/10/98 | |
Ulhas Dhuppad
PSD | President | - | - |
Alind Sharma
PSD | President | - | 01/06/22 |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 16/11/17 |
Nikhil Amin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Harish Kuber
CMP | Compliance Officer | - | 02/02/17 |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 01/01/83 |
Cherylann Pinto
BRD | Director/Board Member | 56 | 06/10/99 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 59 | 14/08/20 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 06/10/99 |
Chief Executive Officer | 54 | 12/10/98 | |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 01/01/83 |
Director/Board Member | 83 | 14/08/09 | |
Director/Board Member | 68 | 10/02/23 | |
Director/Board Member | 48 | 01/04/19 | |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 16/11/17 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 282 188 156 | 138 368 096 ( 49,03 %) | 0 | 49,03 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
9 609 571 | 7.84% | 89 329 419 $ |
Información de la empresa
Glenmark Pharmaceuticals Ltd.
Glenmark House Off Western Express Highway
400099, Mumbai
+91 22 4018 9999
http://www.glenmarkpharma.comEmpresas del grupo
Nombre | Categoría y sector |
---|---|
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Sector
Ventas por región
Revisiones del BPA
Ganancias trimestrales - Tasa de sorpresa
Varia. 1 de ene. | Capi. | |
---|---|---|
+26,39 % | 3652,13 M | |
+19,62 % | 43,34 mil M | |
+20,44 % | 21,96 mil M | |
+10,86 % | 14,09 mil M | |
+13,07 % | 13,64 mil M | |
+37,46 % | 11,43 mil M | |
-8,59 % | 6863,13 M | |
-0,05 % | 6787,61 M | |
-8,87 % | 5725,52 M | |
+8,46 % | 5216,04 M |
- Bolsa de valores
- Acciones
- Acción GLENMARK
- Empresa Glenmark Pharmaceuticals Limited